National Health (Pharmaceutical Benefits - Therapeutic Groups) Amendment Determination 2014 (No. 1) (No. PB 23 of 2014)

Overview

The National Health (Pharmaceutical Benefits – Therapeutic Groups) Amendment Determination 2014 (No. 1) is an instrument made under the National Health Act 1953, aimed at addressing a specific issue within the pharmaceutical benefits framework by amending the National Health (Pharmaceutical Benefits – Therapeutic Groups) Determination 2010. This amendment was enacted to remove certain listed drugs from their respective therapeutic groups, a necessary step in response to the introduction of price disclosure and price reduction measures under section 99ADH of the Act, effective from 1 April 2014. The Minister for Health has the authority to make such determinations under subsection 84AG(1) of the Act, which allows for the classification of therapeutic groups and the inclusion of drugs within them. This legislative instrument does not require additional consultation as it is deemed minor and consequential to the aforementioned price disclosure and reduction measures, and it aligns with human rights by facilitating access to affordable medications, thereby supporting the highest attainable standard of health. The National Health Act 1953, administered by the Australian Parliament, was enacted to provide for national security in health matters and to establish a framework for the administration of health services and benefits. This particular amendment determination was introduced to ensure the smooth implementation of pricing reforms within the Pharmaceutical Benefits Scheme (PBS), which is a cornerstone of Australia's health system. The policy objective is to maintain the integrity and effectiveness of the PBS by ensuring that drugs are appropriately categorised within therapeutic groups, particularly in light of new pricing regulations. This amendment is effective from 1 April 2014, and it is compatible with human rights as it does not raise any issues under the International Covenant on Economic, Social and Cultural Rights.

Scope and Application

The National Health (Pharmaceutical Benefits – Therapeutic Groups) Amendment Determination 2014 (No. 1) applies to the classification and grouping of pharmaceutical drugs under the National Health Act 1953. Specifically, this instrument amends the National Health (Pharmaceutical Benefits – Therapeutic Groups) Determination 2010 to remove certain listed drugs from their respective therapeutic groups. This applies to drugs such as Rabeprazole, which is removed from the Proton pump inhibitor group, effective from 1 April 2014. The amendment is consequential to the application of price disclosure and price reduction measures under section 99ADH of the Act. The determination is applicable nationally as it pertains to the Pharmaceutical Benefits Scheme, which is a Commonwealth scheme. There are no exclusions or exemptions specified in this amending determination, and it operates within the framework of the overarching National Health Act 1953. The scope of the Act extends to all entities and persons involved in the supply and administration of pharmaceuticals under the Pharmaceutical Benefits Scheme. Subordinate instruments may further refine the application of this determination as required.

Key Provisions

The National Health (Pharmaceutical Benefits – Therapeutic Groups) Amendment Determination 2014 (No. 1) (the Determination) amends the National Health (Pharmaceutical Benefits – Therapeutic Groups) Determination 2010 (PB 1 of 2010) (the Principal Determination). This amendment, effective from 1 April 2014, primarily concerns the classification of drugs within therapeutic groups under the National Health Act 1953. Section 1(1) of the Determination removes specific listed drugs from their respective therapeutic groups based on the application of section 99ADH of the Act, which pertains to price disclosure and price reductions. In this instance, the drug 'Rabeprazole' is removed from the Proton pump inhibitor (PPI) group, altering its classification and potentially affecting its pharmaceutical benefits. The Determination imposes certain obligations on the entities it governs. It mandates that drugs listed under section 99ADH of the Act must be reclassified if they have at least one listed brand subject to the new pricing regulations. This reclassification ensures that the therapeutic groupings accurately reflect the current regulatory environment. Additionally, healthcare providers and pharmaceutical companies must update their records and systems to reflect these changes, ensuring compliance with the updated therapeutic classifications. Breaches of the Determination may have both civil and criminal consequences, although the specific penalties are not detailed within the Determination itself. Generally, non-compliance with the National Health Act 1953 can lead to penalties under the Act, which may include fines and other administrative sanctions. For more severe breaches, criminal penalties may apply, including imprisonment. The precise penalties would be determined based on the nature and severity of the breach, in accordance with the broader legislative framework provided by the National Health Act 1953. The Determination also includes a Statement of Compatibility with Human Rights, affirming that it is compatible with the human rights and freedoms recognised in international instruments. This compatibility ensures that the amendments do not adversely affect the right to health, as guaranteed by the International Covenant on Economic, Social and Cultural Rights. The role of the Pharmaceutical Benefits Advisory Committee (PBAC) in making evidence-based decisions further supports the progressive realisation of this human right by ensuring that access to medicines remains appropriate and effective.